Image of Carole Diane Mitnick

Carole Diane Mitnick, ScD

Professor of Global Health and Social Medicine

Dr. Mitnick graduated cum laude from the University of Rochester in 1988 with a B.A. in political science and French. She spent 1986-1987 in Paris, France, studying at L’Institut d’Etudes Politiques and L’Université de Paris IV. In 1996, she received a masters in international health epidemiology and ecology from the Harvard School of Public Health, and in 2001 she completed a doctor of science degree in international health epidemiology and ecology, also at the Harvard School of Public Health.

Dr. Mitnick’s research centers on the improvement of clinical management and programmatic policy for tuberculosis and multidrug-resistant tuberculosis (MDR-TB) globally. Dr. Mitnick is a founding investigator of a movement to conduct randomized controlled clinical trials to improve treatment of drug-resistant TB (RESIST-TB). Dr. Mitnick’s work also includes applying marginal structural modeling to MDR-TB treatment data to assess the effect on outcomes of different types of therapy in observational studies. Dr. Mitnick is the principal investigator of an NIAID grant to plan a Phase II clinical trial examining the potential of high-dose rifampin to shorten standard TB therapy. Her research questions are strongly influenced by the mission of Partners In Health, with which Dr. Mitnick has worked since 1996: she strives to conduct research that will effect changes in global policy to ensure the highest standard of care and best treatment outcomes for patients suffering from all forms of tuberculosis, regardless of where they live.

This influence has also driven Dr. Mitnick’s involvement in global policy efforts. She contributed to the original and revised Guidelines for the Programmatic Management of MDR-TB. She sought, through the publication, Randomized trials to optimize treatment of MDR-TB: the time for action is now (PLoS Medicine, 2007), to generate increased support for controlled examination of anti-mycobacterial agents for the treatment of MDR-TB. Through participation in working groups, sub-groups, and task forces of the STOP-TB Partnership, she has co-authored two articles which define research agendas for MDR-TB (Gupta et al., IJTLD, 2003; Cobelens et al., PLoS Medicine 2008) and one that proposed standardized definitions for analysis of MDR-TB treatment outcomes (Laserson et al., IJTLD, 2005). She consults for the Green Light Committee of the World Health Organization for francophone countries implementing programmatic management of MDR-TB. Her efforts extend to capacity building for recording and reporting on the management of drug-resistant TB, as well as to clinical and operational research in Latin America and beyond. She develops and participates in post-graduate trainings, network-building activities, and trial protocols to be implemented within settings of national TB programs around the world.

Effectiveness of Bedaquiline Use beyond Six Months in Patients with Multidrug-Resistant Tuberculosis.
Authors: Authors: Trevisi L, Hernán MA, Mitnick CD, Khan U, Seung KJ, Rich ML, Bastard M, Huerga H, Melikyan N, Atwood SA, Avaliani Z, Llanos F, Manzur-Ul-Alam M, Zarli K, Binegdie AB, Adnan S, Melikyan A, Gelin A, Isani AK, Vetushko D, Daugarina Z, Nkundanyirazo P, Putri FA, Vilbrun C, Khan M, Hewison C, Khan PY, Franke MF.
Am J Respir Crit Care Med
View full abstract on Pubmed
Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications.
Authors: Authors: Rich ML, Khan U, Zeng C, LaHood A, Franke MF, Atwood S, Bastard M, Burhan E, Danielyan N, Dzhazibekova PM, Gadissa D, Ghafoor A, Hewison C, Islam MS, Kazmi E, Khan PY, Lecca L, Maama LB, Melikyan N, Naing YY, Philippe K, Saki NA, Seung KJ, Skrahina A, Tefera GB, Varaine F, Vilbrun SC, Võ L, Mitnick CD, Huerga H.
Int J Tuberc Lung Dis
View full abstract on Pubmed
Estimating post-treatment recurrence after multidrug-resistant tuberculosis treatment among patients with and without HIV: the impact of assumptions about death and missing follow-up.
Authors: Authors: Sauer SM, Mitnick CD, Khan U, Hewison C, Bastard M, Holtzman D, Law S, Khan M, Padayachee S, Ahmed S, Isani AK, Krisnanda A, Vilbrun SC, Bektasov S, Kumsa A, Docteur W, Tintaya K, McNicol M, Atshemyan H, Voynilo T, Thwe TT, Seung K, Rich M, Huerga H, Khan P, Franke M.
medRxiv
View full abstract on Pubmed
Ascertainment Bias in TB Treatment Trials: Can Systematic Assessment of Objective Endpoints Solve It?
Authors: Authors: Mitnick CD, Nunn AJ.
Am J Respir Crit Care Med
View full abstract on Pubmed
Low detection rate of RT-PCR-confirmed COVID-19 using IgM/IgG rapid antibody tests in a large community sample in Lima, Peru.
Authors: Authors: Law S, Tovar MA, Franke MF, Calderon R, Palomino S, Valderrama G, Llanos F, Velásquez GE, Mitnick CD, Lecca L.
BMC Infect Dis
View full abstract on Pubmed
Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective.
Authors: Authors: Rodriguez CA, Lodi S, Horsburgh CR, Mitnick CD, Bastard M, Huerga H, Khan U, Rich M, Seung KJ, Atwood S, Manzur-Ul-Alam M, Melikyan N, Mpinda S, Myint Z, Naidoo Y, Petrosyan O, Salahuddin N, Sarfaraz S, Vilbrun SC, Yae K, Achar J, Ahmed S, Algozhina E, Beauchamp J, de Guadelupe Perea Moreno S, Gulanbaeva M, Gergedava M, Indah Sari CY, Hewison C, Khan P, Franke MF.
PLOS Glob Public Health
View full abstract on Pubmed
The 1/4/6x24 campaign to cure tuberculosis quickly.
Authors: Authors: McKenna L, Frick M, Angami K, Dubula V, Furin J, Harrington M, Hausler H, Heitkamp P, Herrera R, Lynch S, Mitnick CD, Moses GK, Ndjeka N, Nyang'wa BT, Palazuelos L, Ulysse P, Pai M.
Nat Med
View full abstract on Pubmed
Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB.
Authors: Authors: Zeng C, Mitnick CD, Hewison C, Bastard M, Khan P, Seung KJ, Rich ML, Atwood S, Melikyan N, Morchiladze N, Khachatryan N, Khmyz M, Restrepo CG, Salahuddin N, Kazmi E, Dahri AA, Ahmed S, Varaine F, Vilbrun SC, Oyewusi L, Gelin A, Tintaya K, Yeraliyeva LT, Hamid S, Khan U, Huerga H, Franke MF.
Int J Tuberc Lung Dis
View full abstract on Pubmed
Using digital chatbots to close gaps in healthcare access during the COVID-19 pandemic.
Authors: Authors: Tzelios C, Contreras C, Istenes B, Astupillo A, Lecca L, Ramos K, Ramos L, Roca K, Galea JT, Tovar M, Mitnick CD, Peinado J.
Public Health Action
View full abstract on Pubmed
Prevention and management of hearing loss in patients receiving ototoxic medications.
Authors: Authors: Lindeborg MM, Jung DH, Chan DK, Mitnick CD.
Bull World Health Organ
View full abstract on Pubmed